<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7412427\results\search\disease\results.xml">
  <result pre="Targeting Both Virus and Host Factors in Influenza A Virus" exact="Infection" post="SchloerSebastian1GoretzkoJonas1PleschkaStephan2LudwigStephan3https://orcid.org/0000-0001-8892-319Xhttps://sciprofiles.com/profile/397952RescherUrsula1*[1], SebastianMaximilian.Schloer@ukmuenster.deJonas.Goretzko@ukmuenster.de[2], Stephan.Pleschka@viro.med.uni-giessen.de[3], ludwigs@uni-muenster.de *Correspondence: rescher@uni-muenster.de epub: 2020-6-6collection: 2020-7127703received:"/>
  <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Influenza virus" exact="infections" post="and their associated morbidity and mortality are a major"/>
  <result pre="the rapid changes in the influenza virus genome leading to" exact="viral" post="adaptation. Emerging viral resistance to the neuraminidase inhibitor oseltamivir"/>
  <result pre="in the influenza virus genome leading to viral adaptation. Emerging" exact="viral" post="resistance to the neuraminidase inhibitor oseltamivir limits the treatment"/>
  <result pre="resistance to the neuraminidase inhibitor oseltamivir limits the treatment of" exact="acute" post="influenza infections. Targeting influenza virus-host interactions is a new"/>
  <result pre="treatment with oseltamivir and the repurposed antifungal drug itraconazole on" exact="infection" post="of polarized broncho-epithelial Calu-3 cells with pdm09 or Panama"/>
  <result pre="in the combined treatment compared to monotherapy with oseltamivir, permitting" exact="lower" post="concentrations of the drug than required for the single"/>
  <result pre="six decades [1]. However, the high mutation rate of the" exact="viral" post="genome causing continuous changes (antigenic drift) requires a constant"/>
  <result pre="not protect against outbreaks caused by the emergence of new" exact="viral" post="subtypes with new surface glycoproteins due to genome reassortment"/>
  <result pre="shift) [5]. Thus, antiviral drugs are essential additions for effective" exact="infection" post="control. To initiate the infection process, the hemagglutinin (HA)"/>
  <result pre="are essential additions for effective infection control. To initiate the" exact="infection" post="process, the hemagglutinin (HA) protruding from the envelope of"/>
  <result pre="the endosomal membrane, leading to the subsequent release of the" exact="viral" post="genome into the host cell cytosol [8,9]. To avoid"/>
  <result pre="the vital functions of sialic acid residues in the IAV" exact="infection" post="process, the viral NA constitutes an attractive target for"/>
  <result pre="of sialic acid residues in the IAV infection process, the" exact="viral" post="NA constitutes an attractive target for anti-IAV therapy [10,11]."/>
  <result pre="90% of circulating seasonal H1N1 strains in the northern hemisphere" exact="acquired" post="a resistance mutation and became insensitive to oseltamivir [11,12]."/>
  <result pre="is still the leading, most commonly used drug in influenza" exact="infection" post="treatment. The second class of approved antivirals are the"/>
  <result pre="a successful replication process is an emerging approach to counteract" exact="viral infection" post="[19,20,21,22,23]. Because the pathogens critically depend on the host"/>
  <result pre="successful replication process is an emerging approach to counteract viral" exact="infection" post="[19,20,21,22,23]. Because the pathogens critically depend on the host"/>
  <result pre="from host-directed therapy (HDT) would require substantial changes in the" exact="infection" post="cycle and is, therefore, much less likely to occur"/>
  <result pre="crucial role of host cell cholesterol homeostasis in the IAV" exact="infection" post="cycle. Indeed, we could identify the late endosomal cholesterol"/>
  <result pre="in vitro and in a preclinical murine model of IAV" exact="infection" post="[24]. Combination therapy, i.e., the treatment of influenza virus"/>
  <result pre="IAV infection [24]. Combination therapy, i.e., the treatment of influenza" exact="virus infection" post="with at least two drugs with different modes of"/>
  <result pre="infection [24]. Combination therapy, i.e., the treatment of influenza virus" exact="infection" post="with at least two drugs with different modes of"/>
  <result pre="drug oseltamivir and the host-directed anti-infective drug itraconazole on IAV" exact="infection" post="in a cell culture model of polarized bronchial cell"/>
  <result pre="significantly stronger antiviral activities compared to the respective monotherapies, and" exact="lower" post="oseltamivir concentrations were required. Assessment of the mode of"/>
  <result pre="of MÃ¼nster, Germany. Both strains were amplified on MDCK cells." exact="Viral" post="titers were determined via standard plaque assays in MDCK"/>
  <result pre="assays in MDCK cells [26]. 2.2. Cells The human bronchial" exact="epithelial" post="cell lines Calu-3 and the Madin-Darby canine kidney (MDCK)"/>
  <result pre="of the confluent monolayers was measured with a Millicell-ERS (Electrical" exact="Resistance" post="System) voltohmmeter (Merck Millipore, Darmstadt, Germany) and reached around"/>
  <result pre="Germany). Nuclei were visualized with DAPI (300 nM). Z-stacks (11" exact="focal" post="planes/stack) were acquired on an LSM 800 confocal microscope"/>
  <result pre="visualized with DAPI (300 nM). Z-stacks (11 focal planes/stack) were" exact="acquired" post="on an LSM 800 confocal microscope (Carl Zeiss, Jena,"/>
  <result pre="washed with PBS and were inoculated at a multiplicity of" exact="infection" post="(MOI) of 0.1 of virus diluted in infection-PBS (PBS"/>
  <result pre="the solvent DMSO). For assessment of inhibition, the reduction of" exact="viral" post="titers in treated cells was expressed as percentages of"/>
  <result pre="The majority of the most common circulating IAV subtypes already" exact="acquired" post="resistance against the approved antiviral drug amantadine and there"/>
  <result pre="H3N2 isolate A/Panama/2007/99 (Panama) [14,15]. We utilized the human bronchial" exact="epithelial" post="cell line Calu-3 cultured submerged in media on semipermeable"/>
  <result pre="submerged in media on semipermeable supports as an in vitro" exact="infection" post="model. After four days of cultivation, the adherent monolayer"/>
  <result pre="pattern (Figure 1b), indicating successful apicobasal polarization of the confluent" exact="epithelial" post="monolayers. We first tested whether treatment with any of"/>
  <result pre="For both virus subtypes, oseltamivir logEC50 values were shifted toward" exact="lower" post="concentrations required to reach EC50 in the presence of"/>
  <result pre="Figure 9, resulted in consistent patterns across the models. For" exact="infection" post="with pdm09, 0.25 ÂµM itraconazole tended to antagonize oseltamivir"/>
  <result pre="LE compartment is a critical host/pathogen interface in the IAV" exact="infection" post="cycle, since the fusion of the IAV envelope with"/>
  <result pre="found that increased cholesterol accumulation via NPC1 blockade impacts IAV" exact="infection" post="at multiple steps, (i) by impairing the virus/endosome fusion,"/>
  <result pre="a drug-repurposing approach in a preclinical mouse model of IAV" exact="infection" post="[24]. The EC50 values for itraconazole-mediated antiviral activity against"/>
  <result pre="is indeed a promising candidate for the treatment of IAV" exact="infections" post="[24]. Such drugs that target host processes required for"/>
  <result pre="infection. Because they impact basic cell functions, the development of" exact="viral" post="resistance, as is frequently seen with drugs directly targeting"/>
  <result pre="their new use. Mechanistically, host-directed antiviral agents will slow down" exact="viral" post="replication rather than eradicate the virus, and failure of"/>
  <result pre="from the inappropriate time window of application (early vs. late" exact="infection" post="stages) and a suppression rather than a complete elimination"/>
  <result pre="vs. late infection stages) and a suppression rather than a" exact="complete" post="elimination of the infectious agent, requiring long treatment duration"/>
  <result pre="and a suppression rather than a complete elimination of the" exact="infectious" post="agent, requiring long treatment duration which is often associated"/>
  <result pre="at independent drug actions [33]. Notably, we detected significantly decreased" exact="viral" post="titers in the combination treatments when compared to monotherapy"/>
  <result pre="the combination treatments when compared to monotherapy with oseltamivir, at" exact="lower" post="drug concentrations than required for the single treatments. Moreover,"/>
  <result pre="itraconazole might function as a safeguard mechanism to combat IAV" exact="infection" post="caused by strains with heightened oseltamivir resistance. Clinical translation"/>
  <result pre="after oral application [34,35,36]. Absorption from the gastrointestinal tract is" exact="limited" post="because of the low water solubility of this very"/>
  <result pre="impaired by conditions impacting the gastric acidity such as fasting," exact="chronic" post="low gastric acidity, infections, and medications, effective itraconazole levels"/>
  <result pre="S.P. is in part supported by the German Centre for" exact="Infection" post="Research, partner site Giessen (DZIF, TTU 01.806 to S.P.)"/>
  <result pre="4.CarratF.FlahaultA.Influenza vaccine: The challenge of antigenic driftVaccine2007256852686210.1016/j.vaccine.2007.07.02717719149 5.FauciA.S.Emerging and re-emerging" exact="infectious" post="diseases: Influenza as a prototype of the host-pathogen balancing"/>
  <result pre="amantadine-sensitive and -resistant influenza A virusesAntivir. Res.2017140455410.1016/j.antiviral.2017.01.00628087313 18.HeG.QiaoJ.DongC.HeC.ZhaoL.TianY.Amantadine-resistance among H5N1" exact="avian influenza" post="viruses isolated in Northern ChinaAntivir. Res.200877727610.1016/j.antiviral.2007.08.00717897729 19.ShawM.L.The host interactome"/>
  <result pre="and opportunities for antiviral drug discoveryGenome Med.2014611510.1186/s13073-014-0115-125593595 22.KaufmannS.H.E.DorhoiA.HotchkissR.S.BartenschlagerR.Host-directed therapies for" exact="bacterial" post="and viral infectionsNat. Rev. Drug Discov.201817355610.1038/nrd.2017.16228935918 23.ViasusD.PaÃ±o-PardoJ.R.CorderoE.CampinsA.LÃ³pez-MedranoF.VillosladaA.FariÃ±asM.C.MorenoA.RodrÃ­guez-BaÃ±oJ.OteoJ.A.et al.Effect of"/>
  <result pre="for antiviral drug discoveryGenome Med.2014611510.1186/s13073-014-0115-125593595 22.KaufmannS.H.E.DorhoiA.HotchkissR.S.BartenschlagerR.Host-directed therapies for bacterial and" exact="viral" post="infectionsNat. Rev. Drug Discov.201817355610.1038/nrd.2017.16228935918 23.ViasusD.PaÃ±o-PardoJ.R.CorderoE.CampinsA.LÃ³pez-MedranoF.VillosladaA.FariÃ±asM.C.MorenoA.RodrÃ­guez-BaÃ±oJ.OteoJ.A.et al.Effect of immunomodulatory therapies"/>
  <result pre="Pharmacokinetics of Itraconazole after Intravenous or Oral Administration to Rats:" exact="Intestinal" post="First-Pass EffectAntimicrob. Agents Chemother.2004481756176210.1128/AAC.48.5.1756-1762.200415105131 36.AllegraS.FatigusoG.De FranciaS.FavataF.PirroE.CarcieriC.De NicolÃ²A.CusatoJ.Di PerriG.Dâ€™AvolioA.Pharmacokinetic evaluation"/>
  <result pre="Itraconazole and Its Active Metabolite, 7-Hydroxyitraconazole, When Coadministered With a" exact="Vitamin C" post="Beverage in Healthy ParticipantsJ. Clin. Pharmacol.20115144445110.1177/009127001036555720400647 Figure 1 Establishment"/>
  <result pre="Pharmacol.20115144445110.1177/009127001036555720400647 Figure 1 Establishment of polarized monolayers of the airway" exact="epithelial" post="cell line Calu-3 cultured on semipermeable supports. (a) Transepithelial"/>
  <result pre="indicated concentrations for 16 h. Data represent mean percentages of" exact="viral" post="titers Â± SEM, with mean virus titer in control"/>
  <result pre="Figure 4 Individual virus titers obtained in all experimental samples." exact="Viral" post="titers obtained in cells infected with (a) pdm09 and"/>
  <result pre="indicated combinations 2 h p.i. Mean percentages of reduction in" exact="viral" post="titers Â± SEM, with mean virus titer in control"/>
  <result pre="to 100%; n = 3. Dotted line, 90% reduction in" exact="viral" post="titer. Figure 7 Analysis of the anti-IAV activity of"/>
  <result pre="p.i. For each oseltamivir concentration, mean percentages of reduction in" exact="viral" post="titers Â± SEM were compared to the respective oseltamivir"/>
  <result pre="2 h p.i. Colored cells indicate â‰¥90% significant reduction in" exact="viral" post="titers. Combinations with higher inhibitory activities than the respective"/>
  <result pre="indicate significant differences in antiviral activities when the reduction in" exact="viral" post="titersâ€‰found with the combined treatments was compared to the"/>
 </snippets>
</snippetsTree>
